Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8556859 | 0.98 | HRH3 (0.52) | HRH3MAPTSIGMAR1RAD52CYP1A2 | |
| SCHEMBL8557810 | 0.82 | KEAP1 (0.48) | SIGMAR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8555711 | 0.82 | KEAP1 (0.48) | SIGMAR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8557644 | 0.82 | KEAP1 (0.48) | SIGMAR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8558962 | 0.80 | KEAP1 (0.50) | SIGMAR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL11036023 | 0.75 | HRH3 (0.56) | HRH3MAPTSIGMAR1CYP1A2MAPK1 | |
| SCHEMBL9371058 | 0.74 | HRH3 (1.00) | HRH3MAPTSIGMAR1CYP1A2MAPK1 | |
| SCHEMBL3156252 | 0.74 | HRH3 (1.00) | HRH3MAPTSIGMAR1CYP1A2MAPK1 | |
| SCHEMBL9126300 | 0.74 | HRH3 (1.00) | HRH3MAPTSIGMAR1CYP1A2MAPK1 | |
| SCHEMBL15933346 | 0.74 | HRH3 (1.00) | HRH3MAPTSIGMAR1CYP1A2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0575954-B1 | Aminoalkylcarbamic esters of eseroline suitable for use as cholinesterase acitivity inhibitors and relative preparation process | MEDIOLANUM FARMACEUTICI SRL (IT) | 1998-09-02 | — | — | EP | disclosed |